Almax Pharma SRL
Almax Pharma reported total assets of 346,656 € at the end of the 2025 financial year (annual accounts filed with the NBB on 04 Nov 2025).
The score of Almax Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +14 % Total assets +13 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Almax Pharma's annual accounts
Filed annual accounts
- Year ended 31 Mar 2025filed on 04 Nov 2025
- Year ended 31 Mar 2024filed on 23 Dec 2024
- Year ended 31 Mar 2023filed on 10 Nov 2023
- Year ended 31 Mar 2022filed on 17 Nov 2022
- Year ended 31 Mar 2021filed on 20 Aug 2021
Almax Pharma's financial analysis
- Solvency87.5%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Almax Pharma
Almax Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0556.705.368
- VAT number
- BE0556705368
- Peppol
- Registered · 0208:0556705368 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Jul 2014
- Registered office
- 5651 Walcourt
- Latest accounts
- 2025 · filed on 04 Nov 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Almax Pharma (SRL) has been based in Walcourt since 2014, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 2,070 € and equity of 303,429 €; its revenue is not published. Its solvency stands at 87.5%, above the median of its sector (41.5%).
Companies similar to Almax Pharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Joye Retail sale of pharmaceutical products Kortrijk · balance sheet 346,818 €
- ISA Pharma Retail sale of pharmaceutical products Orp-Jauche · balance sheet 346,253 €
- Immo Maeriën-Ghilain Retail sale of pharmaceutical products Kasterlee · balance sheet 348,075 €
- Kerckaert Pharma Retail sale of pharmaceutical products Lievegem · balance sheet 350,343 €
- Vemaco Retail sale of pharmaceutical products Kapelle-op-den-Bos · balance sheet 350,379 €
- Farma Florosa Retail sale of pharmaceutical products Heist-op-den-Berg · balance sheet 350,389 €
- Sauveniere Retail sale of pharmaceutical products Saint-Gilles · balance sheet 351,330 €
- Nathypharm Retail sale of pharmaceutical products Andenne · balance sheet 340,634 €
Frequently asked questions about Almax Pharma
What is the revenue of Almax Pharma?
Almax Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Almax Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0556705368 for Almax Pharma, if the company is VAT-registered. Its company number (CBE) is 0556.705.368.
Where is the registered office of Almax Pharma?
According to the CBE register, the registered office of Almax Pharma is in 5651 Walcourt.
What is the equity of Almax Pharma?
At the close of the 2025 financial year, the equity of Almax Pharma amounts to 303,429 €, a solvency of 87.5% of total assets.
Who manages Almax Pharma?
The register lists 1 active mandates at Almax Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Almax Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →